Our Pricing

Wegovy Discount Code UK: Clinical Evidence and Real Results

Searching for a genuine wegovy discount code uk? At Cured Pharmacy, use code WEIGHTLOSSNEW for 10% off your first Wegovy prescription, starting from £79.00. More importantly, we'll show you the actual clinical trial data that demonstrates why Wegovy (semaglutide) has become the UK's most prescribed weight loss injection, with results backed by peer-reviewed evidence from the landmark STEP trials.

How Wegovy Produces Weight Loss: The STEP Trial Evidence

Wegovy contains semaglutide 2.4mg, a GLP-1 receptor agonist licensed by the MHRA for chronic weight management in adults with a BMI of 30 kg/m² or above, or 27 kg/m² with weight-related comorbidities [1]. The medication works by mimicking the natural hormone GLP-1, which regulates appetite signals in the brain and slows gastric emptying to increase satiety after meals.

The pivotal STEP 1 clinical trial followed 1,961 adults over 68 weeks and demonstrated that participants receiving semaglutide 2.4mg achieved an average body weight reduction of 14.9%, compared to 2.4% in the placebo group [1]. Crucially, 86.4% of participants in the semaglutide group lost at least 5% of their baseline body weight — a threshold associated with clinically meaningful health improvements including reduced cardiovascular risk factors.

In the STEP 3 trial, which combined semaglutide with intensive behavioural therapy, participants achieved an average weight loss of 16.0% over the same period [2]. These results represent the highest efficacy demonstrated by any approved pharmacological weight management treatment available through UK pharmacies, subject to prescriber assessment and suitability.

Real Patient Outcomes: What the Clinical Data Shows

Beyond average weight loss percentages, the STEP trials revealed consistent patterns in how patients respond to Wegovy treatment. In STEP 1, approximately one-third of participants lost 20% or more of their baseline body weight — a magnitude previously achievable only through bariatric surgery [1].

The trials also documented significant improvements in cardiometabolic markers. Participants experienced average reductions in waist circumference of 13.5cm, improvements in systolic blood pressure of 6.2 mmHg, and favourable changes in lipid profiles including reduced triglycerides [1]. For patients with prediabetes at baseline, semaglutide treatment was associated with a 61% lower risk of progression to type 2 diabetes compared to placebo.

Weight loss typically begins within the first 4 weeks of treatment, with the majority of weight reduction occurring between weeks 20 and 60 as patients titrate to the full 2.4mg maintenance dose [2]. The gradual dose escalation protocol — starting at 0.25mg weekly and increasing monthly — helps minimise gastrointestinal side effects that some patients experience during initial treatment phases.

Long-Term Weight Maintenance

The STEP 4 trial specifically examined weight maintenance after initial weight loss, finding that participants who continued semaglutide treatment maintained an average 17.4% total weight loss from baseline, whilst those switched to placebo regained 6.9% [3]. This data demonstrates that ongoing treatment is typically necessary to sustain weight loss outcomes, as discontinuation often results in gradual weight regain over subsequent months.

Who Can Use Wegovy: UK Prescribing Criteria

Wegovy is licensed in the UK for adults with an initial BMI of 30 kg/m² or greater, or 27 kg/m² or greater in the presence of at least one weight-related comorbidity such as hypertension, type 2 diabetes, dyslipidaemia, or obstructive sleep apnoea [4]. At Cured Pharmacy, our UK-registered prescribers assess your eligibility during a free online consultation that takes under 3 minutes to complete.

Treatment is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, and should be used with caution in those with a history of pancreatitis or severe gastrointestinal disease [4]. Your prescriber will review your complete medical history, current medications, and any previous weight management attempts before determining if Wegovy is appropriate for your individual circumstances.

NICE guidance recommends that semaglutide 2.4mg should be discontinued if patients do not achieve at least 5% weight loss after 6 months of treatment at the maintenance dose, as continued use is unlikely to produce clinically meaningful benefits [5]. Our clinical team monitors your progress and provides ongoing support throughout your treatment journey to optimise outcomes.

Wegovy Discount Code UK: How to Access Lower Pricing

At Cured Pharmacy, Wegovy starts from £79.00 per pen, with transparent upfront pricing displayed before you complete your clinical assessment. Use discount code WEIGHTLOSSNEW at checkout to receive 10% off your first prescription — no hidden fees, no subscription traps, and no inflated 'compare at' prices.

Unlike some UK pharmacy providers that advertise low headline prices but add consultation fees, delivery charges, or mandatory subscription commitments, our pricing includes your free clinical assessment by a UK prescriber, dispensing by our GPhC-registered pharmacy team, and discreet delivery to your chosen address. Superintendent pharmacist Tarun Kumar (GPhC 2233073) oversees all prescriptions to ensure compliance with UK regulations and patient safety standards.

We guarantee the lowest prices for genuine UK-licensed Wegovy in the UK market. If you find a lower price from another GPhC-registered pharmacy for the same product and service level, we'll match it. All Wegovy pens are sourced directly from licensed UK wholesalers and stored in our temperature-controlled pharmacy facilities to maintain product integrity.

Prescription Process at Cured Pharmacy

After completing your online assessment, a UK-registered prescriber reviews your information within 24 hours on weekdays. If approved, your prescription is dispensed by our pharmacy team and dispatched via tracked courier in 100% discreet packaging with no external branding. Most patients receive their first Wegovy pen within 2-3 working days of prescription approval, subject to stock availability.

Common Side Effects and Clinical Management

The most frequently reported side effects in the STEP trials were gastrointestinal symptoms, including nausea (44% of participants), diarrhoea (30%), vomiting (24%), and constipation (24%) [1]. These effects were typically mild to moderate in severity and decreased over time as patients adapted to treatment, with most occurring during dose escalation phases.

Approximately 7% of participants in the STEP 1 trial discontinued treatment due to adverse events, compared to 3% in the placebo group [1]. The gradual titration schedule used in clinical practice — increasing the dose every 4 weeks — helps minimise gastrointestinal tolerability issues. Patients are advised to eat smaller portions, avoid high-fat meals, and stay well-hydrated during the initial treatment period.

Rare but serious side effects include acute pancreatitis, gallbladder disease, and hypoglycaemia in patients taking concomitant diabetes medications [4]. Our clinical team provides detailed guidance on warning signs to monitor and when to seek immediate medical attention. All prescription medications dispensed by Cured Pharmacy include comprehensive patient information leaflets with full safety information approved by the MHRA.

Wegovy vs Alternative Weight Loss Treatments

Semaglutide 2.4mg demonstrates superior weight loss outcomes compared to earlier GLP-1 treatments. In head-to-head comparison, semaglutide produced greater weight reduction than liraglutide 3.0mg, with participants losing an average of 15.8% versus 6.4% respectively over 68 weeks [6].

Tirzepatide, a dual GIP/GLP-1 receptor agonist, showed even greater efficacy in the SURMOUNT trials, with the highest dose producing average weight loss of 20.9% over 72 weeks [7]. However, tirzepatide is currently licensed in the UK only for type 2 diabetes management, whilst semaglutide 2.4mg holds specific MHRA approval for chronic weight management in appropriate patients.

Oral medications such as orlistat produce more modest results, with average weight loss of approximately 3-5% when combined with dietary modification [8]. Injectable GLP-1 treatments like Wegovy represent the most effective pharmacological option currently available through UK pharmacies for patients who meet prescribing criteria, though all treatments require ongoing lifestyle modifications including reduced calorie intake and increased physical activity for optimal results.

Choosing the Right Treatment Approach

Your UK prescriber will consider multiple factors when recommending a weight management treatment, including your BMI, previous weight loss attempts, medical history, current medications, and personal preferences regarding injection frequency and tolerability profiles. At Cured Pharmacy, we offer a range of MHRA-licensed weight management treatments, with clinical guidance tailored to your individual circumstances and treatment goals.

Scientific References

1. Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., & Kushner, R. F. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183
2. Wadden, T. A., Bailey, T. S., Billings, L. K., Davies, M., Frias, J. P., Koroleva, A., Lingvay, I., O'Neil, P. M., Rubino, D. M., Skovgaard, D., Wallenstein, S. O. R., Garvey, W. T., & STEP 3 Investigators. (2021). Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity. JAMA, 325(14), 1403–1413. https://doi.org/10.1001/jama.2021.1831
3. Rubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., Lingvay, I., Mosenzon, O., Rosenstock, J., Rubio, M. A., Rudofsky, G., Tadayon, S., Wadden, T. A., Dicker, D., & STEP 4 Investigators. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity. JAMA, 325(14), 1414–1425. https://doi.org/10.1001/jama.2021.3224
4. Novo Nordisk. (2023). Wegovy 2.4 mg solution for injection in pre-filled pen: Summary of Product Characteristics. Electronic Medicines Compendium. https://www.medicines.org.uk/emc/product/13799
5. National Institute for Health and Care Excellence. (2023). Semaglutide for managing overweight and obesity: Technology appraisal guidance [TA875]. NICE. https://www.nice.org.uk/guidance/ta875
6. Rubino, D. M., Greenway, F. L., Khalid, U., O'Neil, P. M., Rosenstock, J., Sørrig, R., Wadden, T. A., Wizert, A., Garvey, W. T., & STEP 8 Investigators. (2022). Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes. JAMA, 327(2), 138–150. https://doi.org/10.1001/jama.2021.23619
7. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., Stefanski, A., & SURMOUNT-1 Investigators. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–218. https://doi.org/10.1056/NEJMoa2206038
8. Yanovski, S. Z., & Yanovski, J. A. (2014). Long-term Drug Treatment for Obesity: A Systematic and Clinical Review. JAMA, 311(1), 74–86. https://doi.org/10.1001/jama.2013.281361

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Weight loss results vary between individuals and depend on multiple factors including adherence to treatment, dietary modifications, and physical activity levels. Clinical trial data represents average outcomes and individual results may differ.